MetaVia Inc. MTVA
We are a clinical-stage biotechnology company focused primarily on developing novel pharmaceuticals to treat cardiometabolic diseases. We have two programs focused primarily on the treatment of metabolic dysfunction-associated steatohepatitis ("MASH") and obesity.
● Vanoglipel (DA-1241) is a novel GPR119 ("GPR119") agonist with development optionality as a standalone or combination therapy for both MASH and Type 2 Diabetes Mellitus ("T2DM"). Agonism of GPR119 in the gut promotes the release of key gut peptides, glucagon-like peptide-1 ("GLP-1"), glucagon-dependent insulinotropic polypeptide receptor ("GIP"), and peptide YY ("PYY"). These peptides play a further role in glucose metabolism, lipid metabolism and weight loss. Vanoglipel (DA-1241) has demonstrated beneficial effects on glucose, lipid profile and liver inflammation, as demonstrated during in-vivo preclinical studies.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| R&D | $6.8M | $21.6M | — | — | — | — | — | — | — | — |
| SG&A | $6.9M | $7.3M | $6.7M | $8.6M | $8.8M | $7.8M | $2.7M | $1.6M | $10.4M | $6.0M |
| Total operating expenses | $13.7M | $28.8M | $15.9M | $19.6M | $15.3M | $29.7M | $20.2M | $15.5M | $33.1M | $14.7M |
| Operating income | -$13.7M | -$28.8M | -$15.9M | -$19.6M | -$15.3M | -$29.7M | -$20.2M | -$15.5M | -$33.1M | -$14.7M |
| Interest expense | $510.0K | $920.0K | $461.0K | — | $14.0K | $39.0K | $22.0K | $40.0K | $286.0K | $114.0K |
| Pre-tax income | -$13.0M | -$27.6M | -$12.5M | -$14.0M | -$15.3M | -$29.7M | -$21.3M | -$15.5M | -$33.4M | -$14.6M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$13.0M | -$27.6M | -$12.5M | -$14.0M | -$15.3M | -$29.7M | -$21.3M | -$15.5M | -$33.4M | -$14.6M |
| EPS, basic | -7.35 | -39.13 | -2.46 | -43.42 | -19.81 | -1.83 | — | — | — | — |
| EPS, diluted | -7.35 | -39.13 | -2.46 | -43.42 | -19.81 | -1.83 | -4.08 | -3.65 | -3.23 | -2.57 |
| Shares, diluted (wtd. avg.) | 1.8M | 705,193 | 5.1M | 321,703 | 771,422 | 16.2M | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $10.3M | $16.0M | $22.4M | $33.4M | $16.4M | $10.1M | $13.9M | $2.8M | $50.0K | $24.0M |
| Total current assets | $10.9M | $16.1M | $22.5M | $33.5M | $16.6M | $10.7M | $14.1M | $3.8M | $19.0M | $24.7M |
| Property, plant and equipment | $17.0K | $34.0K | $46.0K | $2.0K | $110.0K | $155.0K | $200.0K | $3.0K | — | — |
| Total assets | $11.1M | $16.3M | $22.8M | $33.5M | $16.8M | $11.0M | $14.5M | $3.8M | $19.0M | $24.8M |
| Accounts payable | $1.1M | $3.9M | $821.0K | $708.0K | $830.0K | $2.6M | $638.0K | $170.0K | $4.0M | $2.0M |
| Total current liabilities | $5.6M | $8.3M | $6.0M | $11.8M | $2.2M | $3.7M | $2.1M | $219.0K | $6.4M | $4.1M |
| Total liabilities | $5.8M | $8.3M | $6.1M | $11.8M | $2.2M | $3.8M | $2.2M | $360.0K | $15.1M | $4.1M |
| Retained earnings | -$148.8M | -$135.9M | -$108.3M | -$95.8M | -$81.8M | -$66.5M | -$36.9M | -$15.6M | -$60.5M | -$27.1M |
| Total equity | $5.3M | $7.9M | $16.7M | $21.8M | $14.6M | $7.2M | $12.3M | -$13.3M | $25.0K | $20.6M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$15.7M | -$24.7M | -$10.8M | -$11.7M | -$15.1M | -$10.8M | -$7.0M | -$14.5M | -$26.9M | -$11.0M |
| Depreciation and amortisation | $19.0K | $20.0K | $6.0K | $20.0K | $48.0K | $46.0K | $17.0K | — | — | — |
| Stock-based compensation | $411.0K | $538.0K | $222.0K | $854.0K | $662.0K | $699.0K | $118.0K | $4.1M | $5.3M | $1.7M |
| Capital expenditure | $2.0K | $8.0K | $50.0K | — | $3.0K | $4.0K | $214.0K | $3.0K | — | — |
| Investing cash flow | -$2.0K | -$8.0K | -$50.0K | $8.0K | -$586.0K | $69.0K | -$6.1M | -$3.0K | — | — |
| Financing cash flow | $10.0M | $18.3M | -$80.0K | $28.7M | $22.0M | $6.9M | $24.2M | $17.2M | $21.3M | $31.5M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001140361-26-016802.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Net income | -$14.6M | -$33.4M | -$15.5M | -$21.3M | -$29.7M | -$15.3M | -$14.0M | -$12.5M | -$27.6M | -$13.0M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Regulation FD disclosure Item 7.01
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Other event Item 8.01
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Regulation FD disclosure Item 7.01
- Other event Item 8.01
- Regulation FD disclosure Item 7.01
- Regulation FD disclosure Item 7.01
- Results announced Item 2.02
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |